

References I-90

1. Emery P, Burmester G, Bykerk V, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. *Ann Rheum Dis*. 2015;74(1):19-26.
2. Tsuboi H, Matsumoto I, Hagiwara S, et al. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid arthritis with Sjögren's syndrome Endocrinopathy (ROSE) trial —an open-label, one-year, prospective study —Interim analysis of 32 patients for 24 weeks. *Modern Rheumatology*. 2015;25(2):187–93.
3. Ursini F, Russo E, Hribal M, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis. *Medicine*. 2015;94(21):e888.
4. Singh J, Saag K, Bridges S, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research*. 2016;68(1):1-26.
5. Smolen J, Wollenhaupt J, Westhovens R, et al. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naïve patients with Early Erosive rheumatoid arthritis (AGREE). *Arthritis Research & Therapy*. 2015;17:157.
6. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
7. ASHP Guidelines on Home Infusion Pharmacy Services, 2013. Accessed September 2, 2017.
8. MICROMEDEX® SOLUTIONS Compendia. 2019. Abatacept.
9. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Abatacept. 2019.
10. MCG™ Care Guidelines, 21st edition, 22nd edition, 2018, Home Infusion Therapy, CMT : MT0009(SR).

- 11.Maggi L, Cimaz R, Capone M, et al. Immunosuppressive Activity of Abatacept on CirculatingT Helper Lymphocytes from Juvenile Idiopathic Arthritis Patients. *Int Arch Allergy Immunol*. 2016;171:45-53.
- 12.Strand V, Alemao E, Lehman T, et al. Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. *Arthritis Research & Therapy*. 2018;20(1):269.
- 13.Brunner HI, TzaribachevN, Vega CG, et al. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis. *Arthritis & Rheumatology*. 2018;70(7):1144-1154.
- 14.Orencia (abatacept) for injection, for intravenous and subcutaneous use [package insert]. Bristol-Myers Squibb Company. Princeton, NJ. Revised 03/2019.
- 15.Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol*.2008;58:826-50.
- 16.Ringold S, Weiss PF, Colbert RA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. *Arthritis Care Res*. 2014;66(7):1063-1072.
- 17.Singh JA, Saag KG, Bridges Jr SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research*. 2015;1-25.
- 18.Singh JA, Guyatt G, Ogdie A, et al. 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. *Journal of Psoriasis and Psoriatic Arthritis*. 2019; 4(1):31-58.